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PC3TIS21/BTG2 is member of a novel family of antiproliferative genes
(BTG1, ANA/BTG3, PC3B,TOB, and TOB2) that play a role in cellu-
lar di¡erentiation.We have previously shown that PC3TIS21/BTG2 is
induced by nerve growth factor (NGF) at the onset of neuronal
di¡erentiation in the neural crest-derived PC12 cell line, and is a
marker for neuronal birth. We now observe that PC3TIS21/BTG2
ectopically expressed in PC12 cells synergises with NGF, similarly
to the cyclin-dependent kinase inhibitor p21, potentiating the
induction of the neuronal markers tyrosine hydroxylase and
neuro¢lament160kDa. Furthermore, PC3TIS21/BTG2 protects from
apoptosis elicited by NGF deprivation in terminally di¡erentiated
PC12 cultures. Such e¡ects might be a consequence of the arrest
of cell cycle exertedby PC3TIS21/BTG2, or expression of a sensitising
(neurogenic) property of the molecule. NeuroReport 13:417^422
c 2002 LippincottWilliams &Wilkins.
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INTRODUCTION
The process of neural development is the result of a
regulatory network that coordinates cell cycle and neuro-
genic genes. Cell cycle control seems to have a role in both
neural determination and terminal differentiation, as well as
in neuronal survival (for review see [1]).
In this process might be involved the gene PC3 (also
known as TIS21 or BTG2), originally isolated as an
immediate early gene activated at the onset of the neuronal
differentiation triggered by nerve growth factor (NGF) in
the neural crest-derived rat PC12 chromaffin cell line [2],
and prototype member of a novel family of antiproliferative
genes that play a role in cellular differentiation (namely,
BTG1, BTG3/ANA, PC3B, TOB, and TOB2) (for review see
[3]). PC3 was also isolated in mouse NIH3T3 cells as a
tetradecanoyl phorbol acetate-induced sequence, TIS21 [4]
and, more recently, in human, called BTG2. This latter
turned out to be induced by p53 and by p73, and to be
involved in cell survival after genotoxic response [5,6].
In addition to the observation that PC3 is rapidly induced
following the NGF-dependent differentiation of the PC12
cells, other evidence suggested its involvement in neuronal
differentiation. PC3 mRNA was found to be transiently
expressed in the ventricular zone of the neural tube [2,7],
with a correlation to the period and to the area where the
neuroblast becomes post-mitotic and starts to differentiate
into a mature neuron [7]. PC3 is therefore a marker for
neuronal birth. Subsequent studies further clarified that
PC3/TIS21 identifies single neuroepithelial cells that switch
from proliferative to neuron-generating division [8]. In fact,
the PC3/TIS21 mRNA and protein was found to be
expressed during the G1 phase in the susbset of neuro-
epithelial (NE) cells of the neural tube, identified by the
early neuronal differentiation marker bIII-tubulin, and for a
short period in the post-mitotic neuronal daughter cell [8].
Given that the change in the division mode of NE cells, from
symmetrical to asymmetrical (i.e. generating one post-
mitotic neuron and one NE cell), determines the onset of
neurogenesis, this again correlates the expression of PC3/
TIS21to the onset of neurogenesis.
More recent data shed light on the mechanism by which
PC3 inhibits cell cycle, indicating that this occurs through
the inhibition of cyclin D1 transcription [9]. The key
regulator of cell cycle, pRb, functions as inhibitor of G1
entry when in a dephosphorylated state, whereas pRb
phosphorylation by the cyclin-dependent kinase 4 (CDK4),
associated with its partner cyclin D1, inactivates its growth-
suppressing activity. Thus, a reduced expression of cyclin
D1, caused by PC3, inactivates CDK4 and leads in the end to
the activation of pRb, with a consequent arrest in G1 (for
review see [10]).
These data, in conjuction with our demonstration that
PC3 inhibits cell proliferation also in PC12 cells ([11]; see
also below) suggested that PC3 might have a role in
neuronal differentiation as inducer of the growth arrest
required for differentiation [7].
We evaluated this hypothesis in the same neuronal
cellular system in which PC3 was cloned, and observed
that, although unable to autonomously trigger differentia-
tiont of PC12 cells, PC3 potentiated the differentiation
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elicited by NGF and enhanced the survival of cells under-
going apoptosis following forced de-differentiation.
MATERIALS AND METHODS
Cell culture, cell lines and transfections: PC12 cells
(originally obtained from D. Schubert, Salk Institute, 5th
passage) were grown in DMEM containing 5% bovine
serum and 5% horse serum (Hy Clone, Logan, Utah) in
10% CO2.
Transfection of the plasmids was performed by the
liposome technique using the Lipofectamine reagent
(Invitrogen, USA), as per manufacturers instructions. The
indicated amount of DNA (see figure legends), diluted in
Optimem containing Lipofectamine (5 or 30 ml for 35 mm or
90 mm dishes, respectively), was added to the cultures, left
to incubate for 18 h, then substituted with normal DMEM.
Plasmids, PC3 expression vectors and mutants: pSCT-bgal
and pSCT-PC3 were constructed as described [9]. In
particular pSCT-PC3 was obtained by cloning into 50 XbaI
and 30 HindIII sites of the pSCT vector the coding region of
PC3 cDNA (nucleotides 65–541, with the stop codon). pCEP-
WAF1/p21 expression vector was from B. Vogelstein [12].
Immunofluorescence staining and antibodies: Transfected
cells, grown on poly-lysine coated coverslips, were treated
for immunofluorescence staining as described [9]. Briefly,
cells were fixed for 20 min at room temperature in PBS
containing 3.75% paraformaldehyde, and incubated, after
PBS washes, for 2 min in 0.1 M glycine–PBS. Permeabilisa-
tion was obtained with 0.2% Triton X-100 in PBS for 4 min at
room temperature and was followed, after a PBS wash, with
a 60 min incubation at room temperature with one, or two
where indicated, primary antibodies, diluted in PBS. A3H
rabbit polyclonal [11] was diluted 1:50, anti-bgal rabbit
polyclonal (Chemicon International Inc., Temecula, CA) was
diluted 1:50, anti-medium-size neurofilament (160 kDa; NF-
M) and anti-tyrosine hydroxylase TH-2 mouse monoclonals
(TH; Sigma Chemicals) were diluted 1:20 and 1:1000,
respectively, whereas the rabbit polyclonal anti-p21 (PC55,
Calbiochem) was diluted 1:20. Secondary antibodies were as
indicated, either FITC- or TRITC-conjugated (tetramethylr-
hodamine isothiocyanate, from Jackson Laboratories, USA).
Cells were mounted with PBS:glycerol (3:1). Immunofluor-
escence was performed on a Leitz Dialux 22 microscope.
Induction of apoptosis by NGF-deprivation and morpholo-
gical evaluation: Apoptosis of neuronal PC12 cell cultures
was induced following a described procedure [13]. Cells
cultured for 10 days with NGF in low serum (to facilitate the
entry of cells in G0 and thus the NGF-induced differentia-
tion) were replated, transfected after 24 h by Lipofectamine
with the indicated constructs, after 48 h deprived of NGF
(also adding an anti-NGF antibody to remove NGF bound
to the receptors), and 20 h later fixed and immunostained.
Morphological evaluation of apoptosis was performed as
described [14]. Briefly, cells successfully transfected were
detected by monitoring bgal, revealed by fixation and
incubation with anti-bgal antibody. Cells were then
mounted and fluorescence was visualised as described
above. Stained nuclei were scored by blind analysis and
categorised according to the condensation and staining of
chromatin. Normal nuclei were identified as non-condensed
chromatin dispersed over the entire nucleus. Apoptotic
nuclei were identified by condensed chromatin, contiguous
to the nuclear membrane, as well as by nuclear fragmenta-
tion of condensed chromatin. In each experiment 12 fields
per plate of about 40 nuclei were counted.
RESULTS
The neural crest-derived chromaffin cells (and the contin-
uous line PC12) in presence of NGF differentiate into
sympathetic neurons [15]. In PC12 cells, PC3 mRNA is
induced by NGF rapidly, with a 15-fold peak at 1 h, and
transiently, being almost undetectable after 3 h [2]. To
evaluate whether PC3 has a role in the onset and/or
maintenance of neuronal differentiation, we over-expressed
PC3 in PC12 cells by transient transfection, and triggered
the differentiation immediately after, by addition of NGF.
After 72 h we analysed the expression of two markers for
neuronal terminal differentiation, TH and NF-M, by
immunofluorescence staining [16,17]. TH is involved in
the synthesis of dopamine and is highly induced during the
differentiation of sympathetic neurons. We observed that
cells positive for ectopic PC3 (detected by the antibody
A3H, [11]) expressed TH very brightly above its basal
background expression, with a frequency more than
doubled with respect to the cells treated with NGF and
transfected with bgal expression construct as control (Fig. 1,
Fig. 3). Similarly, ectopic expression of PC3 was associated
to a significant increase of the cytoplasmic, perinuclear
staining corresponding to the NF-M protein (Fig. 2, Fig. 3).
The same increase in the frequency of expression of the two
neuronal markers was observed in PC12 cells ectopically
expressing the CDK inhibitor p21, consistently with a
previous report indicating that p21 elicits biochemical
changes similar to those induced by NGF (without inducing
differentiation per se; [18]). On the other hand, in the absence
of NGF, the frequency of TH and NF-M expression in cells
positive for ectopic PC3 did not differ from cells ectopically
expressing bgal (Fig. 3). As a whole, this leads us to
conclude that PC3 potentiates the differentiation elicited by
NGF in PC12 cells, but is unable to autonomously trigger
the process of differentiation.
Previous reports indicated that the TIS21/PC3 mRNA
was highly and persistently induced in PC12 cells during
the apoptosis elicited by NGF deprivation (analogously to
what observed for c-jun), suggesting a role for this gene in
the apoptotic process [19]. In considering also that PC3
activates pRb, whose function is essential for neuronal
survival [20], we sought to ascertain whether PC3 played a
role in this process. In fact, withdrawal of NGF from PC12
cell cultures causes their death [15,21], and the process
closely resembles to programmed cell death in neurons
[22,19], making this cell system a suitable model for the
study of such phenomenon. Thus, we induced apoptosis in
terminally differentiated PC12 cell cultures through depri-
vation of NGF and expressed ectopic PC3 by transfecting,
according to a decribed protocol [13], either the empty pSCT
vector, the pSCT-PC3 construct, or the antisense pSCT-PC3
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construct, in conjuction with pSCT-bgal as a transfection
marker.
We observed that over-expression of PC3 significantly
prevented cell death (about 40% decrease of the apoptosis
induced by NGF deprivation), as judged by morphological
evaluation of nuclei stained with Hoechst 33258 dye,
whereas over-expression of antisense PC3 had an opposite
effect (about 70% increase; Fig. 4a,b).
DISCUSSION
It is known that the decision of a cell to differentiate is often
made in the G1 phase of the cell cycle; in the neuron, the
progressive restriction of growth potential from stem cell to
neural precursor correlates with the number of cell
divisions, and a correct terminal differentiation requires
correlation with the exit from cell cycle. In some cellular
systems enforced cell cycle arrest achieved by over-expres-
sing inhibitors of CDKs is sufficient to cause differentiation.
Moreover, differentiation in situations of deregulated pro-
liferation is usually abnormal or results in cell death. In
PC12 cells, for instance, it has been observed that inhibition
of CDKs protects differentiated cultures from apoptosis [23].
The PC12 cell system represents a model for terminal
differentiation, triggered by NGF, given that chromaffin
cells, derived from neural crest progenitors, are already
determined to the neuronal lineage. Recently, cell cycle
genes have been directly implicated in the differentiation of
PC12 cells. In fact it has been shown that the concomitant
inhibition of CDK2 and Cdc2, or the over-expression of
Rb2/p130, a member of the Rb family, is sufficient per se to
cause differentiation of PC12 cells [24,25]. The inhibition of
CDK2 and Cdc2 in PC12 cells, which leads to the full
activation of pRb-mediated arrest in G1 and to induction of
differentiation, seems to stand for cell cycle arrest in itself as
cause for terminal differentiation. In the case of Rb2/p130,
we cannot exclude an intrinsic neurogenic activity of that
molecule [25]. Recently the key cell cycle inhibitor p73 has
been shown to induce differentiation of a neuronal cell line
[26]. This action could involve the induction of the CDK
inhibitor p21 but, given that this molecule is not per se
inducing differentiation (at least in PC12 cells; [18]), the
differentiative effect of p73 might be also cell cycle
independent.
PC3 is known to induce cell cycle arrest in PC12 cells and
other cell types (for review see [3]). In fibroblast we have
Fig.1. PC3 potentiates the induction of THbyNGF in PC12 cells. Shown are representative immuno£uorescencephotomicrographs of THexpression in
cultures transfectedwith PC3, bgal or p21. 2  105 PC12 cells were seeded in 35mmdishes coatedwith polylysine. After 24 h cells were transfectedwith
the expressionvectors pSCT-bgal, or pSCT-PC3, or pCEP-WAF1 (2mg each).The following dayNGF (100ng/ml) was added and incubated for 72h (with an
intermediate change of medium).Cells were then ¢xed, permeabilized and stained. PC3, bgal and p21proteins were revealed by staining with goat anti-
rabbit TRITC-conjugated antibody, after incubation with anti-bgal, anti-PC3 (A3H) or anti-p21 polyclonal antibodies. TH was visualized by MabTH-2
followedby goat anti-mouse FITC-conjugated antibody.Nuclei were detectedby Hoechst 33258 dye.The corresponding phase contrast ¢elds are shown
(P.C.). Arrows indicate cells expressing the ectopic proteins. Bar¼15mm.
Vol 13 No 4 25 March 2002 419
CONTROLOF DIFFERENTIATIONANDAPOPTOSIS BY PC3 NEUROREPORT
demonstrated that this occurs through inhibition of CDK4
activity, which is responsible for the primary phosphoryla-
tion event leading to inactivation of pRb, and thus to
progression of the cell cycle [9]. The same functional
inhibition of CDK4, and of CDK2 and Cdc2 as well, is
exerted by p21, that from a functional point acts in parallel
with PC3. Therefore these molecules, both potentiating the
differentiation exerted by NGF, although unable to initiate
autonomously that process, share functional similarity.
Moreover, NGF has been shown to cause arrest of PC12
cells in G1 phase, a decrease of CDKs expression and
activity, with consequent activation of pRb, and an increase
of cyclin D1 and p21 levels [27,28]. These latter changes are
elicited by NGF only in presence of serum, and do not seem
to be required for differentiation ([27,28]; B. Rudkin,
personal communication).
A possible interpretation of our data is that PC3, and p21
as well, potentiates neuronal differentiation as the conse-
quence of its ability to arrest cell cycle, sensitising the cell to
respond more readily to the differentiative stimulus by
NGF. Alternatively, PC3 might also be endowed with
neurogenic properties that in PC12 cells do not find the
proper context, such as appropriate target genes.
PC3 appears to play a direct role in PC12 cell survival,
given its ability to rescue from death elicited by NGF
deprivation a significant fraction of cells. This action is in
Fig. 2. PC3 potentiates the induction of neuro¢lament medium size (NF-M) by NGF in PC12 cells. Shown are representative immuno£uorescence
photomicrographs of NF-M expression in cultures transfected with PC3, bgal or p21.Cells were treated, ¢xed and stained as indicated in Fig.1, except
for the use of anti-NF-M mouse monoclonal, revealed by goat anti-mouse FITC-conjugated antibody.Nuclei were detected by Hoechst 33258 dye.The
corresponding phase contrast ¢elds are shown (P.C.). Arrows indicate cells expressing the ectopic proteins. Bar¼15mm.
Fig. 3. Quantitative analysis of the synergistic e¡ect of PC3 on the in-
duction of TH and NF-M proteins by NGF.Values represent the percen-
tage of cells positive for either TH (grey bars) or NF-M (white bar)
immunoreactivity, after 72 h treatment with NGF (left side) or without
treatment (right side), detected between cells ectopically expressing
PC3, bgal or p21 (as indicated). Means7 s.e.m. are from three indepen-
dent experiments. At least 100 cells were counted for each group. The
statistical analysis indicated was performed by Students t-test.
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line with the hypothesis that neuronal apoptosis results
from the failed attempt to activate cell cycle in terminally
differentiated neurons [29], and is consistent with a
previous report indicating that the apoptosis resulting from
genotoxic stimulus is increased in mouse ES cells deprived
of PC3/TIS21 [5]. Two pathways are essentially activated in
neurons by NGF withdrawal, one triggered by the c-Jun N-
terminal kinase (JNK), the other by CDK4 and CDK6 as a
result of cyclin D1 increase [29], with consequent inactiva-
tion of pRb. The final target of both pathways might be p53
Fig. 4. PC3 prevents the apoptosis induced by deprivation of NGF. 2  106 cells were plated in 90mm collagen-coated dishes, and shifted after 24 h to
DMEMwith1% heat-inactivatedhorse serumcontaining100ng/mlNGF, for10 days (changed three times per week).Cell cultureswere then replated onto
35mm plates coated with polylysine and laminin, adding NGF to the low-serum DMEM. After 24 h the cells were transfected by Lipofectamine with
constructs indicated below. After 48 h PC12 cultures werewashed once in PBS, and incubated in NGF-freemedium, containing anti-NGF polyclonal anti-
body (Sigma) diluted1:400.Twenty hours after NGF withdrawal, cells were ¢xed for immunostaining. (a) Representative immuno£uorescence photomi-
crographs of cells treated as outlined above, transfected with either 1.5mg pSCT empty vector (VEC), 1.5mg pSCT-PC3 (PC3), or 1.5mg pSCT-PC3
antisense (PC3-AS), andwith 0.5mg pSCT-bgal as transfectionmarker.Transfected cells are visualized by anti-bgal antibody, followedby goat anti-rabbit
FITC-conjugated secondary antibody; nuclei are stained by Hoechst 33258 dye. Arrows indicate the transfected cells. (b) Percentage of cells showing
apoptotic nuclearmorphology, after treatment as in panel (a).Means7 s.e.m. are from three independentexperiments.The total number of cells positive
for transfection, analyzed in the three experiments, is indicated at the top of the bar. *po 0.05 vs vector-transfected cell (Students t-test).
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that could activate death genes as BAX (for review see [30])
or cell cycle arrest genes such as p21 or PC3.
CONCLUSION
PC3 is an NGF-inducible immediate early gene, whose
induction by NGF in PC12 cells is independent from the
presence or absence of serum (unlike p21 [11]) and is
transient. In fact its expression is barely detectable in
differentiated cells. Thus, considering also the present data,
PC3 might play a physiological role at the onset of PC12
cells differentiation, acting as transient signal for activation
or repression of down stream target genes of cell cycle or
other pathways. A role of PC3 in the maintenance of
differentiation seems less likely. Similarly, PC3 might
promote survival after NGF deprivation by inhibiting the
re-entry into cell cycle, as a result of its ability to prevent
pRb inactivation, possibly by reduction of cyclin D1 levels.
REFERENCES
1. Ohnuma S, Philpott A and Harris WA. Curr Opin Neurobiol 11, 66–73
(2001).
2. Bradbury A, Possenti R, Shooter EM et al. Proc Natl Acad Sci USA 88,
3353–3357 (1991).
3. Tirone F. J Cell Physiol 187, 155–165 (2001).
4. Fletcher BS, Lim RW, Varnum BC et al. J Biol Chem 266, 14511–14518
(1991).
5. Rouault JP, Falette N, Gue´henneux F et al. Nature Genet 14, 482–486 (1996).
6. Zhu J, Jiang J, Zhou W et al. Cancer Res 58, 5061–5065 (1998).
7. Iacopetti P, Barsacchi G, Tirone F et al. Mech Dev 47, 127–137 (1994).
8. Iacopetti P, Michelini M, Stuckmann I et al. Proc Natl Acad Sci USA 96,
4639–4644 (1999).
9. Guardavaccaro D, Corrente G, Covone F et al. Mol Cell Biol 20, 1797–1815
(2000).
10. Sherr CJ and Roberts JM. Genes Dev 13, 1501–1512 (1999).
11. Montagnoli A, Guardavaccaro D, Starace G et al. Cell Growth Diff 7,
1327–1336 (1996).
12. el-Deiry WS, Tokino T, Velculescu VE et al. Cell 75, 817–825 (1993).
13. Xia Z, Dickens M, Raingeaud J et al. Science 270, 1326–1331 (1995).
14. Oberhammer FA, Pavelka M, Sharma S et al. Proc Natl Acad Sci USA 89,
5408–5412 (1992).
15. Greene LA. J Cell Biol 78, 747–755 (1978).
16. Li XM, Qi J, Juorio AV et al. J Neurosci Res 47, 449–454 (1997).
17. Lindenbaum MH, Carbonetto S, Grosveld F et al. J Biol Chem 263,
5662–5667 (1988).
18. Erhardt JA and Pittman RN. J Biol Chem 273, 23517–23523 (1998).
19. Mesner PW, Epting CL, Hegarty JL et al. J Neurosci 15, 7357–7366 (1995).
20. Slack RS, El-Bizri H, Wong J et al. J Cell Biol 140, 1497–1509 (1998).
21. Greene LA, Aletta JM, Rukenstein A et al. Methods Enzymol 147, 207–216
(1986).
22. Scott SA and Davies AM. J Neurobiol 21, 630–638 (1990).
23. Park DS, Farinelli SE and Greene LA. J Biol Chem 271, 8161–8169 (1996).
24. Dobashi Y, Shoji M, Kitagawa M et al. J Biol Chem 275, 12572–12580 (2000).
25. Paggi MG, Bonetto F, Severino A et al. Oncogene 20, 2570–2578 (2001).
26. De Laurenzi V, Raschell G, Barcaroli D et al. J Biol Chem 275, 15226–15231
(2000).
27. van Grunsven LA, Thomas A, Urdiales JL et al. Oncogene 12, 855–862
(1996).
28. Yan GZ and Ziff EB. J Neurosci 15, 6200–6212 (1995).
29. Kranenburg O, van der Eb A and Zantema A. EMBO J 15, 46–54 (1996).
30. Kaplan DR and Miller FD. Curr Opin Neurobiol 10, 381–391 (2000).
Acknowledgements:We thankdelio Mercanti for the gift of NGF.This work has been fundedby DonazioneMaria Bianchi and from
the European Community Grant QLG3-CT-2000-00072.G.C. is supportedby a Fellowship from Associazione Italiana Ricerca sul
Cancero.
42 2 Vol 13 No 4 25 March 2002
NEUROREPORT G.CORRENTE,D.GUARDAVACCAROANDF.TIRONE
